People In Health Care
Dr Marina Berbic
Genetic Pathologist and Deputy Director of Genetics
Douglass Hanly Moir Pathology
Dr Marina Berbic is a genetic pathologist and the Deputy Director of Genetics at Douglass Hanly Moir Pathology – a laboratory based in Sydney and part of Sonic Healthcare. The genetics department at Douglass Hanly Moir offers a wider array of genetic tests across many domains, and the medical leadership model ensures the highest possible standard of care and commitment to patient safety.
Australian Health Journal spoke to Dr Berbic about her career and being a genetic pathologist. She started as a junior doctor in obstetrics and gynaecology after completing a medical degree, though never thought about specialising in pathology. The more she learned about genetic pathology, the more intrigued she became, realising that this specialty aligned with both her strengths and interests.
Dr Berbic has always been interested in science, technology, and innovation. She first studied for a Bachelor of Medical Science degree, followed by a Master’s in Reproductive Health and Human Genetics and then a PhD in Reproductive Medicine. Dr Berbic has long-standing academic interests, both from a research and teaching perspective. She continues to be involved in medical education at the University of New South Wales in her role as an Adjunct Senior Lecturer.
After completing her specialist training and attaining fellowship of the Royal College of Pathologists of Australasia, she commenced her role as a genetic pathologist at Douglass Hanly Moir and later became the Deputy Director of Genetics department. Her role involves providing clinical governance and medical leadership that governs all aspects of medical testing in genetics.
In this interview, Dr Berbic talks about the exciting area of genetic pathology impacting multiple areas of medicine including paediatrics, obstetrics and gynaecology, cardiology, neurology, oncology, and other fields.
The results of genetic testing have a potential impact on the patient’s diagnosis, the decisions that couples may take when they’re making reproductive decisions, and also have predictive implications. The testing results may influence therapy, selection, or patient management and may have far ranging impact on the individual as well as their family.
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
Paramedics seek team-based primary health care pilots
The Chief Executive Officer of The Australasian College of Paramedicine, John Bruning spoke with Australian Health Journal about the following:
New models of care proposed for paramedics
Paramedicine pilot program in the pre-budget submission
Scope of how paramedics can support General Practice, and guidelines on safety and quality
Current limitations experienced by paramedics needing to be addressed by Government
Other health priorities hopefully addressed in Federal Budget.In the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
